Improving health-related quality of life in chronic obstructive pulmonary disease

Current Opinion in Pulmonary Medicine

Volumn 10, Issue 2, 2004, Pages 120-127

  Santo Tomas, Linus H ^a   Varkey, Basil ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Chronic obstructive pulmonary disease (COPD); Health related quality of life (HRQOL)

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; IPRATROPIUM BROMIDE; OPIATE; SALMETEROL; SALMETEROL XINAFOATE; TIOTROPIUM BROMIDE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DRUG USE; HEALTH CARE UTILIZATION; HUMAN; LUNG RESECTION; OUTCOMES RESEARCH; OXYGEN THERAPY; QUALITY OF LIFE; RESOURCE ALLOCATION; REVIEW; SIDE EFFECT;

EID: 1642528866     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200403000-00006     Document Type: Review

References (74)

1. Testa MA, Simonson DC: Assessment of quality-of-life outcomes. N Engl J Med 1996, 334:835-840.
2. Jones PW, Kaplan RM: Methodological issues in evaluating measures of health as outcomes for COPD. Eur Respir J Suppl 2003, 41:13s-18s. This short but instructive review addresses the major concerns involved in selecting health outcome measurements in COPD.
3. Miravitlles M, Alvarez-Sala JL, Lamarca R, et al.: Treatment and quality of life in patients with chronic obstructive pulmonary disease. Qual Life Res 2002, 11:329-338.
4. Belman MJ, Botnick WC, Shin JW: Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996, 153:967-975.
5. Hajiro T, Nishimura K, Tsukino M, et al.: A comparison of the level of dyspnea vs disease severity in indicating the health-related quality of life of patients with COPD. Chest 1999, 116:1632-1637.
6. Mahler DA, Harver A: A factor analysis of dyspnea ratings, respiratory muscle strength, and lung function in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1992, 145:467-470.
7. Curtis JR, Anderson K, Cannella KAS, et al.: American Thoracic Society-Quality of Life Resource. Last site update: June 2003. Available at: http://www.atsqol.org/. Accessed Oct. 23, 2003. A very helpful online resource. Provides practical information on several generic and disease-specific HRQOL instruments, including availability, cost, and contact information for interested users.
8. Wyrwich KW, Fihn SD, Tiemey WM, et al.: Clinically important changes in health-related quality of life for patients with chronic obstructive pulmonary disease: an expert consensus panel report. J Gen Intern Med 2003, 18:196-202.
9. Curtis JR, Patrick DL: The assessment of health status among patients with COPD. Eur Respir J Suppl 2003, 41:36s-45s. This review presents the basic concepts of health status assessment and provides an overview of some HRQOL instruments commonly used in the study of COPD patients.
10. Jones PW: Health status measurement in chronic obstructive pulmonary disease. Thorax 2001, 56:880-887.
11. Ware JE Jr, Sherboume CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-483.
12. Ware JE Jr, Gandek B: Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol 1998, 51:903-912.
13. Gandek B, Ware JE Jr, Aaronson NK, et al.: Tests of data quality, scaling assumptions, and reliability of the SF-36 in eleven countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998, 51:1149-1158.
14. Ware JE Jr, Gandek B: Methods for testing data quality, scaling assumptions, and reliability: the IQOLA Project approach. International Quality of Life Assessment. J Clin Epidemiol 1998, 51:945-952.
15. Desikan R, Mason HL, Rupp MT, et al.: Health-related quality of life and healthcare resource utilization by COPD patients: a comparison of three instruments. Qual Life Res 2002, 11:739-751.
16. Moy ML, Ingenito EP, Mentzer SJ, et al.: Health-related quality of life improves following pulmonary rehabilitation and lung volume reduction surgery. Chest 1999, 115:383-389.
17. Guyatt GH, Berman LB, Townsend M, et al.: A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987, 42:773-778.
18. Jones PW, Quirk FH, Baveystock CM, et al.: A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992, 145:1321-1327.
19. Hunt SM, McEwen J, McKenna SP: Measuring health status: a new tool for clinicians and epidemiologists. J R Coll Gen Pract 1985, 35:185-188.
20. Bergner M, Bobbitt RA, Pollard WE, et al.: The sickness impact profile: validation of a health status measure. Med Care 1976, 14:57-67.
21. Bergner M, Bobbitt RA, Carter WB, et al.: The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981, 19:787-805.
22. Lareau SC, Carrieri-Kohlman V, Janson-Bjerklie S, et al.: Development and testing of the Pulmonary Functional Status and Dyspnea Questionnaire (PFSDQ). Heart Lung 1994, 23:242-250.
23. Weaver TE, Narsavage GL, Guilfoyle MJ: The development and psychometric evaluation of the Pulmonary Functional Status Scale: an instrument to assess functional status in pulmonary disease. J Cardpulm Rehabil 1998, 18:105-111.
24. Tu S, McDonell M, Spertus J, et al.: A new self-administered questionnaire to monitor health-related quality of life in patients with COPD. Ambulatory Care Quality Improvement Project (ACQUIP) Investigators. Chest 1997, 112:614-622.
25. Gerardi DA, Lovett L, Benoit-Connors ML, et al.: Variables related to increased mortality following out-patient pulmonary rehabilitation. Eur Respir J 1996, 9:431-435.
26. Yohannes AM, Baldwin RC, Connolly M: Mortality predictors in disabling chronic obstructive pulmonary disease in old age. Age Ageing 2002, 31:137-140.
27. Crockett AJ, Cranston JM, Moss JR, et al.: The impact of anxiety, depression and living alone in chronic obstructive pulmonary disease. Qual Life Res 2002, 11:309-316.
28. Anthonisen NR, Wright EC, Hodgkin JE: Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986, 133:14-20.
29. Gerardi D, ZuWallack R: Non-pulmonary factors affecting survival in patients completing pulmonary rehabilitation. Monaldi Arch Chest Dis 2001, 56:331-335.
30. Domingo-Salvany A, Lamarca R, Ferrer M, et al.: Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002, 166:680-685. This study indicates that in a cohort of COPD patients observed over 5 years the baseline HRQOL is a significant predictor of mortality independent of FEV1. They suggest that thorough evaluation of COPD should include HRQOL assessment.
31. Almagro P, Calbo E, Ochoa de Echaguen A, et al.: Mortality after hospitalization for COPD. Chest 2002, 121:1441-1448.
32. Fan VS, Curtis JR, Tu SP, et al.: Ambulatory Care Quality Improvement Project I. Using quality of life to predict hospitalization and mortality in patients with obstructive lung diseases. Chest 2002, 122:429-436. This is a large prospective cohort study of patients with obstructive lung disease that found significant association between HRQOL and the study outcomes of hospitalization and all-cause mortality.
33. Burge PS, Calverley PM, Jones PW, et al.: Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000, 320:1297-1303.
34. Thompson WH, Carvalho P, Souza JP, et al.: Controlled trial of inhaled fluticasone propionate in moderate to severe COPD. Lung 2002, 180:191-201.
35. van der Valk P, Monninkhof E, van der Palen J, et al.: Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 2002, 166:1358-1363. This randomized, double-blind, placebo-controlled study found increased exacerbations and deterioration in health status of patients who discontinued inhaled fluticasone.
36. van den Boom G, Rutten-van Molken MP, Molema J, et al.: The cost effectiveness of early treatment with fluticasone propionate 250 microg twice a day in subjects with obstructive airway disease. Results of the DIMCA program. Am J Respir Crit Care Med 2001, 164:2057-2066.
37. Wise R, Connett J, Weinmann G, et al.: Group ftLHSR. Effect of Inhaled Triamcinolone on the Decline in Pulmonary Function in Chronic Obstructive Pulmonary Disease. N Engl J Med 2000, 343:1902-1909.
38. Fabbri L, Hurd SS: Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update. Eur Respir J 2003, 22:1-2.
39. Pauwels RA, Buist AS, Ma P, et al.: Committee GS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): Workshop Report, updated Nov. 2003. Available at: http://www.goldcopd.com/. Accessed Nov. 10, 2003. This updated consensus on different aspects of COPD provides a comprehensive guide to health care givers. More recent evidence has been reviewed and considered in revising recommendations.
40. Sestini P, Renzoni E, Robinson S, et al.: Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002:CD001495.
41. Guyatt GH, Townsend M, Keller JL, et al.: Should study subjects see their previous responses: data from a randomized control trial. J Clin Epidemiol 1989, 42:913-920.
42. Mahler DA, Donohue JF, Barbee RA, et al.: Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999, 115:957-965.
43. Dahl R, Greefhorst LA, Nowak D, et al.: Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164:778-784.
44. Appleton S, Poole P, Smith B, et al.: Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev. 2002:CD001104.
45. Liesker JJ, Van De Velde V, Meysman M, et al.: Effects of formoterol (Oxis Turbuhaler) and ipratropium on exercise capacity in patients with COPD. Respir Med 2002, 96:559-566.
46. Wadbo M, Lofdahl CG, Larsson K, et al.: Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study. Eur Respir J 2002, 20:1138-1146.
47. Hvizdos KM, Goa KL. Tiotropium bromide. Drugs 2002, 62:1195-1203; discussion 1204-1205.
48. Vincken W, van Noord JA, Greefhorst AP, et al.: Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002, 19:209-216. This randomized, controlled study indicates that tiotropium is superior to ipratropium in improving symptoms, health status, and lung function.
49. Brusasco V, Hodder R, Miravitlles M, et al.: Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003, 58:399-404.
50. Donohue JF, van Noord JA, Bateman ED, et al.: A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002, 122:47-55.
51. Tashkin D, Kesten S: Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003, 123:1441-1449.
52. The COMBIVENT Inhalation Solution Study Group: Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 1997, 112:1514-1521.
53. COMBIVENT Inhalation Aerosol Study Group: In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994, 105:1411-1419.
54. D'Urzo AD, De Salvo MC, Ramirez-Rivera A, et al.: In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3-week, randomized, double-blind, within-patient. Multicenter Study. Chest 2001, 119:1347-1356.
55. Calverley P, Pauwels R, Vestbo J, et al.: Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003, 361:449-456. [Published erratum appears in Lancet 2003, 10:1660.] This large randomized trial, with three active treatment arms and a placebo arm, demonstrates that the combination of an inhaled corticosteroid and long-acting β-2 agonist may provide benefit beyond what is offered by either component alone.
56. Nannini L, Lasserson T, Poole P: Combined corticosteroid and long-acting beta-agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2003, 4:CD003794.
57. Jennings AL, Davies AN, Higgins JP, et al.: A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002, 57:939-944. The data synthesized in this systematic review provides valuable information on the use of opioids for dyspnea. It helps to answer who may benefit and what route may be effective. Majority of the patients had COPD.
58. Jennings AL, Davies AN, Higgins JPT, et al.: Opioids for the palliation of breathlessness in terminal illness. Cochrane Database Syst Rev 2003, 3:3.
59. Poole PJ, Veale AG, Black PN: The effect of sustained-release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157:1877-1880.
60. Eaton T, Garrett JE, Young P, et al.: Ambulatory oxygen improves quality of life of COPD patients: a randomised controlled study. Eur Respir J 2002, 20:306-312. The study provides some evidence that ambulatory oxygen may positively affect HRQOL in patients who have satisfactory oxygenation at rest but desaturate with exertion. However, it also raises questions of compliance with this therapy.
61. Lacasse Y, Brosseau L, Milne S, et al.: Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002: CD003793. This is an excellent systematic review on the effects of pulmonary rehabilitation in COPD.
62. Ries AL, Kaplan RM, Limberg TM, et al.: Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 1995, 122:823-832.
63. Brooks D, Krip B, Mangovski-Alzamora S, et al.: The effect of postrehabilitation programmes among individuals with chronic obstructive pulmonary disease [comment]. Eur Respir J 2002, 20:20-29.
64. Ries AL, Kaplan RM, Myers R, et al.: Maintenance after pulmonary rehabilitation in chronic lung disease: a randomized trial. Am J Respir Crit Care Med 2003, 167:880-888.
65. Wedzicha JA, Bestall JC, Garrod R, et al.: Randomized controlled trial of pulmonary rehabilitation in severe chronic obstructive pulmonary disease patients, stratified with the MRC dyspnoea scale. Eur Respir J 1998, 12:363-369.
66. Cilione C, Lorenzi C, Dell Orso D, et al.: Predictors of change in exercise capacity after comprehensive COPD inpatient rehabilitation. Med Sci Monit 2002, 8:CR740-CR745.
67. Covey MK, Larson JL, Wirtz SE, et al.: High-intensity inspiratory muscle training in patients with chronic obstructive pulmonary disease and severely reduced function. J Cardpulm Rehabil 2001, 21:231-240.
68. Sanchez Riera H, Montemayor Rubio T, Ortega Ruiz F, et al.: Inspiratory Muscle Training in Patients With COPD: Effect on Dyspnea, Exercise Performance, and Quality of Life. Chest 2001, 120:748-756.
69. Monninkhof EM, van der Valk PD, van der Palen J, et al.: Self-management education for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2003:CD002990.
70. Watson PB, Town GI, Holbrook N, et al.: Evaluation of a self-management plan for chronic obstructive pulmonary disease. Eur Respir J 1997, 10:1267-1271.
71. Gallefoss F, Bakke PS, Rsgaard PK: Quality of life assessment after patient education in a randomized controlled study on asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999, 159:812-817.
72. Bourbeau J, Julien M, Maltais F, et al.: Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med 2003, 163:585-591. Though the improvement in HRQOL was seen mainly in the impact subscale of the SGRQ, this study showed significant reduction in health care utilization among patients who were educated on self-management.
73. Fishman A, Martinez F, Naunheim K, et al.: A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003, 348:2059-2073. This randomized, controlled trial is a landmark study. Though the subgroup analysis may be subject to criticism, the insights provided by the study are invaluable.
74. Goldstein RS, Todd TR, Guyatt G, et al.: Influence of lung volume reduction surgery (LVRS) on health related quality of life in patients with chronic obstructive pulmonary disease. Thorax 2003, 58:405-410. This is another notable randomized trial on LVRS that looks at HRQOL as a primary outcome.